GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
0.4140
-0.0003 (-0.07%)
Mar 31, 2026, 10:50 AM EDT - Market open
GT Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
13.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 27.00K | -34.00K | -55.74% |
| Dec 31, 2014 | 61.00K | -307.00K | -83.42% |
| Dec 31, 2013 | 368.00K | 26.00K | 7.60% |
| Dec 31, 2012 | 342.00K | 316.00K | 1,215.38% |
| Dec 31, 2011 | 26.00K | 15.00K | 136.36% |
| Dec 31, 2010 | 11.00K | -37.00K | -77.08% |
| Dec 31, 2009 | 48.00K | -1.10M | -95.80% |
| Dec 31, 2008 | 1.14M | -581.00K | -33.70% |
| Dec 31, 2007 | 1.72M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGTBP News
- 4 weeks ago - GT Biopharma Reports Full Year 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference - GlobeNewsWire
- 2 months ago - GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3 - GlobeNewsWire
- 2 months ago - GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers - GlobeNewsWire
- 2 months ago - EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment - Benzinga
- 3 months ago - Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 - PRNewsWire
- 4 months ago - GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials - Accesswire
- 4 months ago - GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire